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Abstract  
 
Atrial fibrillation (AF) and heart failure (HF) often coexist, 
and the prognosis of patients who have both these conditions is 
worse than those with either condition alone. Heart failure with 
preserved ejection fraction (HFpEF) is a clinical condition that 
was initially characterized as diastolic dysfunction HF, then as 
HF with normal ejection fraction, and more recently as HFpEF. 
About one-third of patients with HFpEF suffer from AF. 
Although, both clinical entities share common pathophysiologic 
mechanisms, current knowledge of the relationship between AF 
and HFpEF is limited. Catheter ablation, although data from 
randomized trials in this category of patients are limited, seems 
to have beneficial effects regarding maintenance of sinus rhythm 
and re-hospitalization rates. Rhythmos 2020;15(2):29-32.  
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Abbreviations: AF = atrial fibrillation; AV = atrioventricular; 
HF = heart failure; HFpEF = heart failure with preserved ejection 
fraction; HFrEF = heart failure with reduced ejection fraction; 
LV = left ventricular; LVEF = left ventricular ejection fraction; 
TICM = tachycardia-induced cardiomyopathy 
  
Introduction 
 
Heart failure (HF) with preserved ejection fraction 
(HFpEF) is a common clinical syndrome, associated with 
high morbidity and mortality rates and currently represents 
approximately 50 % of HF cases.1 HFpEF is mainly a 
clinical diagnosis, consisting of typical HF symptoms in 
patients with left ventricular ejection fraction (LVEF) 
50%.2 The diagnostic criteria include both elevated levels 
of natriuretic peptides and echocardiographic evidence of 
left ventricle diastolic dysfunction or structural heart 
disease.2 Epidemiological data from large clinical trials, 
such as the Framingham Heart Study, have shown that 
patients with HFpEF are usually older overweight women 
with a high prevalence of comorbidities including atrial 
fibrillation (AF).3 Nowadays, about 30 and 25 million 
patients suffer from AF and HF, respectively.4,5 Both AF 
and HF have high prevalence but also, they share common 
pathophysiological mechanisms. The combination of these 
conditions is associated with worse clinical outcomes and 
higher rates of hospitalization. Most of the data are derived 
from clinical trials of patients with heart failure with 
reduced ejection fraction (HFrEF). However, HFpEF 
accounts for up to 50% of prevalent HF, and is thought to 
be more closely related to AF than HFrEF.1, Thus, in the 
Framingham Heart Study, the presence of AF was more 
strongly linked to incident HFpEF than HFrEF.3 Overall, 
62% of patients with HFpEF had AF at any time, which 
was significantly higher than the HFrEF cohort in the 
Framingham cohort. Moreover, the presence of AF may be 
a marker of more advanced HFpEF and worse exercise 
tolerance.6 Atrial fibrillation is mostly presented as 
asymptomatic paroxysmal AF, so the diagnosis can be 
easily missed.7 Additionally, patients with AF could 
exhibit symptoms, such as dyspnea and impaired exercise 
tolerance, which could overlap with HFpEF, making 
difficult the diagnosis. 
 
Pathophysiology 
 
Risk factors that predispose to HFpEF and AF  
 
Many of patients with HFpEF who experience AF 
during the course of their disease, share common risk 
factors and pathophysiological mechanisms. 
Comorbidities and risk factors include diabetes mellitus, 
obesity, coronary artery disease, obstructive sleep apnea, 
smoking and hypertension.8 It is known that systemic 
inflammation plays an important role in the 
pathophysiology process in both HF and AF (Fig. 1). 
Additionally, we know that the incidence of AF increases 
in older patients and the age-related left ventricular 
diastolic dysfunction contributes to the occurrence of AF.9 
 
 
 
Figure 1. Common risk factors and pathophysiologic 
mechanisms between atrial fibrillation (AF) and heart failure 
with preserved ejection fraction (HFpEF). ANS = autonomic 
nervous system 
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AF as the cause of HFpEF 
 
Atrial fibrillation itself could directly lead to HFpEF 
via left atrium dilatation and loss of atrial systole, which 
impairs the diastolic left ventricular (LV) function and 
subsequently the cardiac output. In sinus rhythm atrial 
contraction is estimated to contribute up to 20% of the 
cardiac output. It is noteworthy that atrial systole in adults 
> 50 years old is responsible for up to 70% of ventricular 
filling.10 During AF the contractile coordination between 
atria and ventricles (atrioventricular-AV dyssynchrony) 
worsens the diastolic LV function causing HF symptoms. 
Furthermore, atrioventricular annular remodeling with 
progressive mitral and tricuspid regurgitation may be 
another mechanism by which AF causes HFpEF.11 
Additionally, AF with rapid ventricular response causes 
shortening of diastolic intervals without significant 
worsening in systolic function.12 
Left ventricular fibrosis is found in many patients with 
HFpEF and despite LV hypertrophy due to hypertension, 
AF plays a primary role in the pathophysiologic process.8 
The presence of persistent AF has been reported as an 
independent predictor of LV fibrosis, regardless of ejection 
fraction.8 In the same study paroxysmal AF did not predict 
LV fibrosis at the same degree as permanent AF.8 The AF-
induced ventricular fibrosis has been related primarily to 
the tachycardia induced cardiomyopathy (TICM).13  TICM 
is a reversible systolic dysfunction associated with some 
types of tachyarrhythmias (commonly AF) or high burden 
of premature ventricular beats. The exact mechanisms 
underlying TICM are not fully defined, but include 
subclinical ischemia, abnormalities in energy metabolism, 
redox stress and calcium overload and most data are 
derived from patients with HFrEF.14 Underlying histologic 
changes are characterized by cardiomyocyte lengthening 
and hyperplasia, extracellular matrix changes, myocardial 
fibrosis, myofibril misalignment, loss of sarcomere 
register, and apoptosis.15 Beyond the high heart rate during 
AF, the asynchronous myocardial contraction can lead to 
LV dysfunction.15 
 
HFpEF as the cause of AF 
 
Echocardiographic data from patients with HFpEF 
show, in most of the cases, structural and electrical 
remodeling of the left atrium (LA) which is related with 
high incidence of AF and atrial fibrosis.  Compared to age-
matched control subjects in the general population, 
patients with HFpEF have 68% larger LA volumes.16 
Increased left atrium stretch leads to anisotropy with 
increased dispersion of refractoriness leading to an 
increased vulnerability to AF.17,18 Underlying histologic 
changes include abnormal electrical coupling between 
cardiomyocytes through gap junctions involving atrial 
connexin proteins and loss of cell-to-cell coupling in areas 
of fibrosis.19 All these processes lead to electrical 
remodeling and increased atrial refractoriness and 
development of re-entry circuits predisposing to AF.20,21  
Inflammatory cytokines in addition to the upregulation 
of the autonomic sympathetic system and the renin-
angiotensin-aldosterone system contribute to the 
development of structural remodeling of the left atrium.22 
High adrenergic activity seems to play an important role 
not only on the initiation but on the maintenance of AF, as 
well.23 Elevated natriuretic peptide levels and increased 
sarcoplasmic reticulum calcium content, increases 
afterdepolarizations originating from the pulmonary veins 
which have been recognized as the triggers for AF.24,25 
 
Prognosis of patients with HFpEF and AF 
 
It is known that the presence of AF in patients with HF 
increases the mortality rates compared to HF patients 
without AF (HR: 1.30 and 2.45, respectively).26 The type 
of HF seems to have a different impact on outcomes. Data 
from a meta-analysis have shown that all-cause mortality 
was significantly higher in patients with HFrEF and AF 
than in those with HFpEF and AF (RR: 1.24; 95% CI: 1.12 
to 1.36; p < 0.001). However, the hospitalization and 
stroke rates were similar between the two groups.27 
Women with HFpEF and AF had worse prognosis 
compared to men, as noted in the I-PRESERVE study.28 
From the same study, data have shown that stroke rates in 
HFpEF patients were doubled in those with a history of 
AF, regardless of whether they were in AF at the time of 
assessment.29 
 
Role of catheter ablation in patients with AF and 
HFpEF 
 
Catheter ablation, compared with amiodarone therapy, 
significantly reduces recurrent AF in patients with HFrEF. 
In general, patients with HF have a high recurrence of AF 
and more frequently require repeat ablation procedures. 
CASTLE‐AF showed the efficacy of rhythm control by AF 
ablation in patients with HFrEF.30 Machino‐Ohtsuka et al. 
first demonstrated the safety and efficacy of AF ablation in 
patients with coexisting AF and HFpEF, showing a success 
rate of 73% with one or two procedures and 
pharmacotherapy, and improved diastolic function 
associated with sinus rhythm.31 In another retrospective 
analysis, Black‐Maier et al concluded that procedure 
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success rate and functional improvement after AF ablation 
were similar in HFrEF and HFpEF.32 Moreover, Machino‐
Ohtsuka et al showed that rhythm control in AF‐HFpEF 
via either ablation or medication led to a significantly 
reduced composite of cardiovascular death and HF 
hospitalization compared with rate control.31 
Recently, Fukui et al presented the results of a single‐
center, retrospective analysis of 85 consecutive AF‐
HFpEF patients who received either catheter ablation or 
antiarrhythmic drugs and/or beta‐blockers. AF ablation 
was performed with pulmonary vein antrum isolation 
(PVAI) plus focal ablation, superior vena cava ablation, 
and cavotricuspid isthmus linear ablation.33 The primary 
endpoint was re-hospitalization due to HF. During a mean 
follow‐up of 792 days, more patients in the ablation group 
were free from HF hospitalization (P = 0.039) and in the 
multivariate analysis, catheter ablation was the only factor 
that reduced the re-hospitalizations due to HF (OR = 0.15; 
P < 0.001). As regards the sinus rhythm maintenance, no 
significant difference was seen between the two groups 
(P=0.119).  According to the National Heart, Lung, and 
Blood Institute report, AF ablation in HFpEF is one of the 
major unmet research needs in this field.33 Currently, only 
one study on this field, Treatment of Atrial Fibrillation In 
Preserved Cardiac Function Heart Failure (TAP‐CHF, 
NCT04160000), is currently active and is scheduled to be 
completed by 2024. 
 
Conclusion 
 
AF-HFpEF is a complex clinical entity and the global 
burden of both diseases is going to increase as the 
population ages, and the prevalence of comorbidities like 
hypertension, diabetes mellitus, obesity, and coronary 
artery disease is increasing. Currently, stroke and systemic 
embolism prophylaxis is the only therapy known to reduce 
mortality among patients with AF-HFpEF. Catheter 
ablation seems to have beneficial effects in these patients 
regarding the hospitalization rates. However, randomized 
clinical trials are warranted to confirm the hypothesis that 
achieving long‐term sinus rhythm by ablation, will have 
impact on the reduction of hard end points, such as the 
mortality and the stroke rates. 
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